Background: Quality of individual cases of safety reports (ICSR) is a challenge for modern drug safety studies. Purpose and Research Design: In this cross-sectional study of the safety database, we studied reports completeness for direct oral anticoagulants (DOAC) received in 2017–2022. Study sample: A total of 1428 ICSRs were selected for analysis. Results: The largest number of reports was received for rivaroxaban (638), and the number of records for apixaban and dabigatran was 454 and 336, respectively. The number of reports in the reporting period increased for apixaban only. The number of empty fields per report was 47.5% (52.5% for apixaban, 47.5% for rivaroxaban, and 37.5% for dabigatran). The worst-filled field was the dose of the drug (8.96%). The VigiGrade (VG) score for all reports was 0.268 (rivaroxaban—0.268, apixaban—0.233, and dabigatran—0.353). The VG index was higher for reports received from healthcare professionals (0.441) and authorized authorities (0.397). The proportion of well-documented cases decreased between 2017 and 2022, accounting for 1.82% overall. The average median score (0.44) was achieved in 22.34% cases. Possible main reasons for the decline in quality include the COVID-19 pandemic and the coinciding transition to a new version of the database. Conclusions: Solutions to the problem of low-quality reports may include increasing the staffing, trainings, and introducing electronic control systems.
GottliebMMoyerEBernardK. Epidemiology of pulmonary embolism diagnosis and management among United States emergency departments over an eight-year period. Am J Emerg Med2024; 85: 158–162, Available from. https://www.sciencedirect.com/science/article/pii/S0735675724004571[cited 2024 Nov 24]. [Internet].
2.
LinDSLoHHuangK, et al.Efficacy and safety of direct oral anticoagulants for stroke prevention in older patients with atrial fibrillation: a network meta‐analysis of randomized controlled trials. JAHA2023; 12(23): e030380, [cited 2024 Nov 8]. [Internet].
3.
Abatzis-PapadopoulosMTigkiropoulosKNikasS, et al.The effectiveness and safety of direct oral anticoagulants compared to conventional pharmacologic thromboprophylaxis in hip fracture patients: a systematic review and meta-analysis of randomized controlled trials. Orthop Traumatol Surg Res2023; 109(2): 103364, Available from. https://www.sciencedirect.com/science/article/pii/S1877056822002006[cited 2024 Nov 26]. [Internet].
4.
NavarAMKolkailahAAOvertonR, et al.Trends in oral anticoagulant use among 436 864 patients with atrial fibrillation in community practice, 2011 to 2020. JAHA2022; 11(22): e026723, [cited 2024 Nov 11]. [Internet].
5.
IyerGSTesfayeHKhanNF, et al.Trends in the use of oral anticoagulants for adults with venous thromboembolism in the US, 2010–2020. JAMA Netw Open2023; 6(3): e234059, Available from. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2802739[cited 2024 Nov 7]. [Internet].
6.
MatveevAVGlagolevSVSychevDADepartment of Clinical Pharmacology and Therapy n.a. Acad. B.E. Votchal, Russian Medical Academy of Continuous Professional Education, Moscow, Russia. Consumption of oral anticoagulants in hospitals of the Russian Federation: analysis of the dynamics of procurement data. Pharma2023; 30: 98–106, Available from. https://pharmateca.ru/archive/article/44195[cited 2025 Feb 4]. [Internet].
7.
MatveevAVGlagolevSVKoryanovaKN, et al.Hospital consumption of direct oral anticoagulants in regions of the Russian Federation in 2017–2022. Farm farmakol (Pâtigorsk)2024; 11(6): 461–470, Available from. https://www.pharmpharm.ru/jour/article/view/1398[cited 2025 Feb 4]. [Internet].
8.
BaybulatovaEAChenkurovMSKorovyakovaEA, et al.Direct oral anticoagulants’ consumption and expenditure in the COVID-19 pandemic in Russia and clinical practice guidelines for their use. Pharmacoepidemiology2023; 3(1): 1–32, Available from. https://www.mdpi.com/2813-0618/3/1/1[cited 2025 Oct 27]. [Internet].
9.
YanVKCLiHLWeiL, et al.Evolving trends in consumption of direct oral anticoagulants in 65 countries/regions from 2008 to 2019. Drugs2023; 83(4): 315–340[cited 2024 Nov 11]. [Internet].
10.
BergvallTNorénGNLindquistM. vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf2014; 37(1): 65–77[cited 2025 Oct 27]. [Internet].
11.
DubrallDChristPDomgörgenS, et al.Factors associated with the completeness of information provided in adverse drug reaction reports of physicians, pharmacists and consumers from Germany. Sci Rep2025; 15(1): 23751, Available from. https://www.nature.com/articles/s41598-025-07973-9[cited 2025 Oct 27]. [Internet].
12.
ChooSMSartoriDLeeSC, et al.Data-driven identification of factors that influence the quality of adverse event reports: 15-year interpretable machine learning and time-series analyses of VigiBase and QUEST. JMIR Med Inform2024; 12: e49643, Available from. https://medinform.jmir.org/2024/1/e49643[cited 2025 Oct 28]. [Internet].
13.
NiuRXiangYWuT, et al.The quality of spontaneous adverse drug reaction reports from the pharmacovigilance centre in Western China. Expet Opin Drug Saf2019; 18(1): 51–58[cited 2025 Oct 27]. [Internet].
14.
DurrieuGJacquotJMègeM, et al.Completeness of spontaneous adverse drug reaction reports sent by general practitioners to a regional pharmacovigilance centre: a descriptive study. Drug Saf2016; 39(12): 1189–1195[cited 2025 Oct 27]. [Internet].
15.
PlessisLGómezAGarcíaN, et al.Lack of essential information in spontaneous reports of adverse drug reactions in Catalonia—a restraint to the potentiality for signal detection. Eur J Clin Pharmacol2017; 73(6): 751–758[cited 2025 Oct 27]. [Internet].
16.
BergvallTNorénGNLindquistM. Correction to: vigigrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf2019; 42(6): 805[cited 2025 Oct 27]. [Internet].
17.
TsuchiyaMObaraTMiyazakiM, et al.The quality assessment of the Japanese adverse drug event report database using vigiGrade. Int J Clin Pharm2020; 42(2): 728–736[cited 2025 Oct 27]. [Internet].
18.
MatlalaMFLubbeMSSteynH. The completeness of adverse drug reaction reports in South Africa: an analysis in VigiBase®. Afr J Prim Health Care Fam Med2023; 15(1): e1–e9, Available from. https://www.phcfm.org/index.php/PHCFM/article/view/3659[cited 2025 Oct 28]. [Internet].
HammerOHarperDRyanP. PAST: paleontological statistics software package for education and data analysis. Palaeontol Electron2001; 4: 1–9.
22.
von ElmEAltmanDGEggerM, et al.The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol2008; 61(4): 344–349.
23.
DedefoMGKassieGMGebreyohannesEA, et al.Comparison of the completeness of spontaneously reported adverse drug reactions by consumers, healthcare professionals, and pharmaceutical companies: an evaluation of databases from two high‐income countries. Pharmacol Res Perspect2025; 13(4): e70164[cited 2025 Oct 28]. [Internet].
